Würzburg, Germany – December 2004

vasopharm BIOTECH GmbH – a German biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cerebro- and cardiovascular diseases and their consequences - announced today the successful closing of a new financing round. In line with this financing round vasopharm was able to gain a new investor, the Entrepreneurs Fund B.V., Amsterdam, Netherlands. With regard to this investment, the Entrepreneurs Fund B.V. is represented by its affiliated company Medivita GmbH, Düsseldorf, Germany. The existing investors 3i Group LP, London, UK and Future Capital AG, Frankfurt am Main, Germany also contributed to this round of financing.

The proceeds will fund the completion of the pre-clinical development of vasopharms NOS inhibitor VAS 203 in the indication of traumatic brain injury. After completing the acute tox study vasopharm plans entering a combined Clinical Phase I/II in 2005.

Wuerzburg, Germany and Chesterfield, MO, USA – October 2004

vasopharm BIOTECH and Pfizer Inc. have signed an agreement, under which Pfizer obtains a worldwide, non-exclusive license from vasopharm BIOTECH to its human soluble guanylate cyclase (sGC) enzyme.

Under the terms of the agreement, Pfizer obtains the right to use sGC for preclinical screening purposes. This agreement aids Pfizer in the development of new drug candidates which interfere with the nitric oxide signaling cascade of which sGC represents the main receptor for nitric oxide.

sGC further provides an important second messenger system for the regulation of protein kinases, phosphodiesterases and ion channels. This license agreement is valid until the expiration of vasopharm BIOTECH's patent.

vasopharm BIOTECH is a German biopharmaceutical company active in the discovery and development of novel therapeutics to treat cerebro- and cardiovascular diseases. The company specializes in the nitric oxide signaling cascade and currently focuses on the development of a new drug for the treatment of traumatic brain injury. The pharmacology targets cerebral vessels and tissue simultaneously, a completely new approach in the therapy of brain trauma. With this strategy it became possible to prevent the life threatening rise of intracranial pressure in animals occurring after brain trauma.

Moreover, vasopharm is developing broad band NOX inhibitors which will allow to treat cardiovascular diseases elicited by endothelial dysfunction in a causative manner.

Wuerzburg, Germany – February 2004

The Bavarian Research Foundation supports a collaboration between vasopharm BIOTECH GmbH, the University of Giessen and the University of Wuerzburg with a high level grant. No financial terms were disclosed.

The supported research program entitled Dysregulation of the redox balance in the endothelium - role of the NAD(P)H oxidases and new therapeutic approaches aims at the development of an entirely new class of drugs. These drugs should eventually allow treating diseases like atherosclerosis and chronic hypertension causatively and even may prevent the development of these diseases when applied prophylactically in patients at risk.

vasopharm BIOTECH is dedicated to the development of innovative therapies for the treatment of cerebro- and cardiovascular diseases.

vasopharm BIOTECH aims to treat the underlying cause of cardiovascular diseases, the so called endothelial dysfunction. This means, that the inner layer of vessels, the endothelium, is no longer capable in an adequate regulation of the vascular tone. This is caused by oxidative stress, i.e. an overproduction of free radicals. The main source of these radicals are hyperactive NAD(P)H oxidases. Inhibition of these enzymes may allow the prevention and causal therapy of cardiovascular diseases for the first time ever.